CPC
TEVA icon

Cookson Peirce & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Cookson Peirce & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,249,126
Closed -$27.5M – 313
2024
Q4 		$27.5M Sell
1,249,126
-14,346
-1% -$261K 1.25% 26
2024
Q3 		$22.8M Buy
+1,263,472
New +$22.1M 1.07% 30

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Cookson Peirce & Co's TEVA Position: Q1 2025 in Review

Cookson Peirce & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 1,249,126 shares — an estimated $27.5M sold.

Cookson Peirce & Co first reported a position in TEVA in Q3 2024 and held it in 2 quarters. The position peaked at $27.5M in Q4 2024. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Cookson Peirce & Co reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Cookson Peirce & Co sold 1,249,126 Teva Pharmaceuticals shares in Q1 2025, an estimated $27.5M.
  • Cookson Peirce & Co first reported a position in Teva Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Cookson Peirce & Co's Teva Pharmaceuticals position peaked at $27.5M in Q4 2024.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Cookson Peirce & Co's 13F filing for Q1 2025, filed 13 May 2025.